Welcome to CDC stacks | Continuing Effectiveness of Serogroup A Meningococcal Conjugate Vaccine, Chad, 2013 - 26666 | Emerging Infectious Diseases
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Continuing Effectiveness of Serogroup A Meningococcal Conjugate Vaccine, Chad, 2013
Filetype[PDF-498.63 KB]


Details:
No Related Documents.
You May Also Like:
  1. Public Health Impact After the Introduction of PsA-TT: The First 4 Years
    Personal Author:
    Diomandé, Fabien V. K.; Djingarey, Mamoudou H.; Daugla, Doumagoum M.; Novak, Ryan T.; Kristiansen, Paul A.; Collard, Jean-Marc; Gamougam, Kadidja; Kandolo, Denis; Mbakuliyemo, Nehemie; Mayer, Leonard; Stuart, James; Clark, Thomas; Tevi-Benissan, Carol; Perea, William A.; Preziosi, Marie-Pierre; Marc LaForce, F.; Caugant, Dominique; Messonnier, Nancy; Walker, Oladapo; Greenwood, Brian;
    Published:
    Nov 15 2015
    Source:
    Clin Infect Dis. 2015; 61(Suppl 5):S467-S472.
    Description:
    During the first introduction of a group A meningococcal vaccine (PsA-TT) in 2010-2011 and its rollout from 2011 to 2013, >150 million eligible people, representing 12 hyperendemic meningitis countries, have been vaccinated.|The new vaccine effective...
    File Type:
    Filetype[PDF - 175.59 KB]
  2. MMWR. Morbidity and mortality weekly report, Vol. 64, no. 41, October 23, 2015
    Corporate Author:
    Centers for Disease Control and Prevention (U.S.)
    Published:
    October 23, 2015
    Series:
    MMWR. Morbidity and mortality weekly report ; v. 64, no. 41
    Description:
    Progress Toward Global Eradication of Dracunculiasis, January 2014–June 2015 -- Progress Toward Poliomyelitis Eradication — Afghanistan, January 2014–August 2015 -- Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Reco...
    File Type:
    Filetype[PDF - 1.16 MB]
  3. Initial validation of a simulation model for estimating the impact of serogroup A Neisseria meningitidis vaccination in the African meningitis belt
    Personal Author:
    Jackson, Michael L.; Diallo, Alpha Oumar; Médah, Isaie; Bicaba, Brice Wilfried; Yaméogo, Issaka; Koussoubé, Daouda; Ouédraogo, Rasmata; Sangaré, Lassané; Mbaeyi, Sarah A.;
    Published:
    Oct 25 2018
    Source:
    PLoS One. 13(10).
    Description:
    We previously developed a mathematical simulation of serogroup A Neisseria meningitidis (NmA) transmission in Burkina Faso, with the goal of forecasting the relative benefit of different vaccination programs. Here, we revisit key structural assumptio...
    File Type:
    Filetype[PDF - 1.03 MB]
  4. Introduction and Rollout of a New Group A Meningococcal Conjugate Vaccine (PsA-TT) in African Meningitis Belt Countries, 2010–2014
    Personal Author:
    Djingarey, Mamoudou H.; Diomandé, Fabien V. K.; Barry, Rodrigue; Kandolo, Denis; Shirehwa, Florence; Lingani, Clement; Novak, Ryan T.; Tevi-Benissan, Carol; Perea, William; Preziosi, Marie-Pierre; LaForce, F. Marc;
    Published:
    Nov 15 2015
    Source:
    Clin Infect Dis. 2015; 61(Suppl 5):S434-S441.
    Description:
    A group A meningococcal conjugate vaccine (PsA-TT) was developed specifically for the African "meningitis belt" and was prequalified by the World Health Organization (WHO) in June 2010. The vaccine was first used widely in Burkina Faso, Mali, and Nig...
    File Type:
    Filetype[PDF - 347.17 KB]
  5. Progress toward the global control of Neisseria meningitidis: 21st century vaccines, current guidelines, and challenges for future vaccine development
    Personal Author:
    Dretler, A. W.; Rouphael, N. G.; Stephens, D. S.;
    Published:
    May 09 2018
    Source:
    Hum Vaccin Immunother. 2018; 14(5):1146-1160.
    Description:
    The control of meningitis, meningococcemia and other infections caused by Neisseria meningitidis is a significant global health challenge. Substantial progress has occurred in the last twenty years in meningococcal vaccine development and global impl...
    File Type:
    Filetype[PDF - 660.63 KB]